Anandamide potentiation of miniature spontaneous excitatory synaptic transmission is mediated via IP3 pathway

Neurochemistry International

Volumn 56, Issue 4, 2010, Pages 590-596

  Sang, Nan ^a   Zhang, Jian ^b   Chen, Chu ^b  

^a SHANXI UNIVERSITY   (China)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cannabinoid receptors; Endocannabinoids; Excitatory postsynaptic currents; Hippocampus; Ryanodine receptor; Vanilloid receptor

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 AMINOETHOXYDIPHENYLBORANE; 3 DEOXY 3 FLUORO INOSITOL 1,4,5 TRISPHOSPHATE; ALICYCLIC HYDROXY COMPOUND; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CAPSAZEPINE; INOSITOL TRISPHOSPHATE 3 KINASE; INOSITOL TRISPHOSPHATE 3 KINASE RECEPTOR; RECEPTOR; RESINIFERATOXIN; RIMONABANT; RYANODINE; RYANODINE RECEPTOR; UNCLASSIFIED DRUG; VANILLOID RECEPTOR; XESTOSPONGIN C;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; EXCITATORY POSTSYNAPTIC POTENTIAL; FATTY ACID ANALYSIS; HIPPOCAMPUS; MOUSE; NERVE CELL; NERVE CELL STIMULATION; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; ELECTROPHYSIOLOGY; ENZYME INHIBITORS; EXCITATORY POSTSYNAPTIC POTENTIALS; GLYCERIDES; HIPPOCAMPUS; INOSITOL 1,4,5-TRISPHOSPHATE; MICE; PATCH-CLAMP TECHNIQUES; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; TRPV CATION CHANNELS;

EID: 77249112178     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.01.001     Document Type: Article

References (56)

1. Alger B.E. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog. Neurobiol. 68 (2002) 247-286
2. Bisogno T., Ligresti A., and Di Marzo V. The endocannabinoid signaling system: biochemical aspects. Pharmacol. Biochem. Behav. 81 (2005) 224-238
3. Bisogno T., Martire A., Petrosino S., Popoli P., and Di Marzo V. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease. Neurochem. Int. 52 (2008) 307-313
4. Carlson G., Wang Y., and Alger B.E. Endocannabinoids facilitate the induction of LTP in the hippocampus. Nat. Neurosci. 5 (2002) 723-724
5. Chevaleyre V., and Castillo P.E. Endocannabinoid-mediated metaplasticity in the hippocampus. Neuron 43 (2004) 871-881
6. Chevaleyre V., Takahashi K.A., and Castillo P.E. Endocannabinoid-mediated synaptic plasticity in the CNS. Ann. Rev. Neurosci. 29 (2006) 37-76
7. Cernak I., Vink R., Natale J., Stoica B., Lea IV P.M., Movsesyan V., Ahmed F., Knoblach S.M., Fricke S.T., and Faden A.I. The "dark side" of endocannabinoids: a neurotoxic role for anandamide. J. Cereb. Blood Flow Metab. 24 (2004) 564-578
8. Cinar R., Freund T.F., Katona I., Mackie K., and Szucs M. Reciprocal inhibition of G-protein signaling is induced by CB(1) cannabinoid and GABA(B) receptor interactions in rat hippocampal membranes. Neurochem. Int. 52 (2008) 1402-1409
9. De Petrocellis L., and Di Marzo V. Lipids as regulators of the activity of transient receptor potential type V1 (TRPV1) channels. Life Sci. 77 (2005) 1651-1666
10. Devane W.A., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
11. Eljaschewitsch E., et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49 (2006) 67-79
12. Freund T.F., Katona I., and Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83 (2003) 1017-1066
13. Gopez J.J., et al. Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury. Neurosurgery 56 (2005) 590-604
14. Hájos N., Ledent C., and Freund T.F. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106 (2001) 1-4
15. Hájos N., and Freund T.F. Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. Chem. Phys. Lipids 121 (2002) 73-82
16. Heifets B.D., and Castillo P.E. Endocannabinoid signaling and long-term synaptic plasticity. Annu. Rev. Physiol. 71 (2009) 283-306
17. Isokawa M., and Alger B.E. Retrograde endocannabinoid regulation of GABAergic inhibition in the rat dentate gyrus granule cell. J. Physiol. 567 (2005) 1001-1010
18. Katona I., Urban G.M., Wallace M., Ledent C., Jung K.M., Piomelli D., Mackie K., and Freund T.F. Molecular composition of the endocannabinoid system at glutamatergic synapses. J. Neurosci. 26 (2006) 5628-5637
19. Kim J., and Alger B.E. Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nat. Neurosci. 7 (2004) 697-698
20. Kozak K.R., Prusakiewicz J.L., and Marnett L.J. Oxidative metabolism of endocannabinoids by COX-2. Curr. Pharm. Design 10 (2004) 659-667
21. Lauckner J.E., Jensen J.B., Chen H.-Y., Lu H.-C., Hille B., and Mackie K. GRP55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 2699-2704
22. Mackie K. Cannabinoid receptors as therapeutic targets. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 101-122
23. Mackie K., and Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players. Am. Assoc. Pharm. Sci. J. 8 (2006) E298-E306
24. Makara J.K., Mor M., Fegley D., Szabo S.I., Kathuria S., Astarita G., Duranti A., Tontini A., Tarzia G., Rivara S., Freund T.F., and Piomelli D. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat. Neurosci. 8 (2005) 1139-1141
25. Marinelli S., Di Marzo V., Berretta N., Matias I., Maccarrone M., Bernardi G., and Mercuri N.B. Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J. Neurosci. 23 (2003) 3136-3144
26. Marsicano G., et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302 (2003) 84-88
27. Mechoulam R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50 (1995) 83-90
28. Melis M., Perra S., Muntoni A.L., Pillolla G., Lutz B., Marsicano G., Di Marzo V., Gessa G.L., and Pistis M. Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J. Neurosci. 24 (2004) 10707-10715
29. Melis M., et al. Protective activation of the endocannabinoid system during ischemia in dopamine neurons. Neurobiol. Dis. 24 (2006) 15-27
30. Movsesyan V.A., Stoica B.A., Yakovlev A.G., Knoblach S.M., Lea IV P.M., Cernak I., Vink R., and Faden A.I. Anandamide-induced cell death in primary neuronal cultures: role of calpain and caspase pathways. Cell Death Differ. 11 (2004) 1121-1132
31. Nyilas R., Dudok B., Urban G.M., Mackie K., Watanabe M., Cravatt B.F., Freund T.F., and Katona I. Enzymatic machinery for endocannabinoid biosynthesis associated with calcium stores in glutamatergic axon terminals. J. Neurosci. 28 (2008) 1058-1063
32. Panikashvili D., Simeonidou C., Ben-Shabat S., Hanus L., Breuer A., Mechoulam R., and Shohami E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413 (2001) 427-531
33. Panikashvili D., Mechoulam R., Beni S.M., Alexandrovich A., and Shohami E. CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. J. Cereb. Blood Flow Metab. 25 (2005) 477-484
34. Panikashvili D., Shein N.A., Mechoulam R., Trembovler V., Kohen R., Alexandrovich A., and Shohami E. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol. Dis. 22 (2006) 257-264
35. Páldyová E., Bereczki E., Sántha M., Wenger T., Borsodi A., and Benyhe S. Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. Neurochem. Int. 52 (2008) 321-328
36. Páldy E., Bereczki E., Sántha M., Wenger T., Borsodi A., Zimmer A., and Benyhe S. CB(2) cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: role of CB(2) receptor in pain. Neurochem. Int. 53 (2008) 309-316
37. Piomelli D. The molecular logic of endocannabinoid signaling. Nat. Rev. Neurosci. 4 (2003) 873-884
38. Ross R.A. Anandamide and vanilloid TRPV1 receptors. Br. J. Pharmacol. 140 (2003) 790-801
39. Ryberg E., et al. The orphan receptor GRP55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152 (2007) 1092-1101
40. Safo P.K., and Regehr W.G. Endocannabinoids control the induction of cerebellar LTD. Neuron 48 (2005) 647-659
41. Sarne Y., and Mechoulam R. Cannabinoids: between neuroprotection and neurotoxicity. Curr. Drug Target CNS Neurol. Dis. 4 (2005) 677-684
42. 2 EP2 receptor. J. Neurosci. 25 (2005) 9858-9870
43. Sang N., Zhang J., and Chen C. Prostaglandin E2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates hippocampal inhibitory synaptic transmission. J. Physiol. (Lond) 572 (2006) 735-745
44. Sang N., and Chen C. Lipid signaling and synaptic plasticity. Neuroscientist 12 (2006) 425-434
45. Sang N., Zhang J., and Chen C. COX-2 oxidative metabolite of endocannabinoid 2-AG enhances excitatory glutamatergic synaptic transmission and induces neurotoxicity. J. Neurochem. 102 (2007) 1966-1977
46. Stella N., Schweitzer P., and Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 388 (1997) 773-778
47. Straiker A., and Mackie K. Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. J. Physiol. 569 (2005) 501-517
48. Sugiura T., kishimoto S., Oka S., and Gokoh M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog. Lipid Res. 45 (2006) 405-446
49. Szabo B., Urbanski M.J., Bisogno T., Di Marzo V., mendiguren A., Baer W.U., and Freiman I. Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol. J. Physiol. 577 (2006) 263-280
50. Van der Stelt M., and Di Marzo V. Endovanilloids: putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur. J. Biochem. 271 (2004) 1827-1834
51. Van der Stelt M., and Di Marzo V. Cannabinoid receptors and their role in neuroprotection. NeuroMolecular. Med. 7 (2005) 37-50
52. Yoshida T., Fukaya M., Uchigashima M., Miura E., Kamiya H., Kano M., and Watanabe M. Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. J. Neurosci. 26 (2006) 4740-4751
53. Yue H.Y., Fujita T., and Kumamoto E. Phospholipase A2 activation by melittin enhances spontaneous glutamatergic excitatory transmission in rat substantia gelatinosa neurons. Neuroscience 135 (2005) 485-495
54. Zhang J., and Chen C. Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J. Biol. Chem. 283 (2008) 22601-22611
55. Zhu P.J., and Lovinger D.M. Persistent synaptic activity produces long-lasting enhancement of endocannabinoid modulation and alters long-term synaptic plasticity. J. Neurophysiol. 97 (2007) 4386-4389
56. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., Julius D., and Hogestatt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400 (1999) 452-457